Eli Lilly: Zepbound superior to Wegovy according to study
(CercleFinance.com) - Eli Lilly reports initial results from the SURMOUNT-5 phase 3b randomized open-label clinical trial, according to which its Zepbound produced an average weight loss of 20.
2%, 47% higher than the 13.7% observed with its competitor Wegovy.
At 72 weeks, Zepbound beat Wegovy on both the primary and five key secondary endpoints in this trial of overweight and obese adults with at least one weight-related medical condition and no diabetes.
Zepbound's overall safety profile was similar to that of previously reported SURMOUNT trials. SURMOUNT-5 results will be published in a peer-reviewed journal and presented at a medical meeting next year.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
2%, 47% higher than the 13.7% observed with its competitor Wegovy.
At 72 weeks, Zepbound beat Wegovy on both the primary and five key secondary endpoints in this trial of overweight and obese adults with at least one weight-related medical condition and no diabetes.
Zepbound's overall safety profile was similar to that of previously reported SURMOUNT trials. SURMOUNT-5 results will be published in a peer-reviewed journal and presented at a medical meeting next year.
Copyright (c) 2024 CercleFinance.com. All rights reserved.